Continuing Education
for Urology & GU Oncology Clinicians

Conference Coverage: SUO 2019 Prostate

Washington, DC (UroToday.com) As part of the SUO 2019 advanced prostate cancer session, Dr. Samuel Denmeade discussed his work with bipolar androgen therapy (BAT) for men with castration resistant prostate cancer (CRPC). Dr. Denmeade reminds us that metastatic prostate cancer remains an incurable disease, with a median overall survival in the CRPC state of three years. The mainstay of treatment is androgen deprivation therapy (ADT), however, it is associated with many side effects:

Non-Accredited

Washington, DC (UroToday.com) In the first prostate cancer session at the 2019 Society for Urologic Oncology meeting in Washington, DC, Dr. Matthew Cooperberg highlighted the similarities between breast cancer and prostate cancer and suggested some lessons that urologic oncologists can draw from the evolution of breast cancer treatment. He credited his colleague at UCSF, Dr. Laura Esserman, for her leadership in breast cancer research and her assistance with the preparation of his talk.

Non-Accredited

Washington, DC (UroToday.com) Dr. Arnulf Stenzl provided the EAU guest lecture today at the 20th Annual Meeting of the Society of Urologic Oncology, discussing his innovative work on improving urologic oncology surgery with intraoperative real-time technology. Dr. Stenzl has more than 600 publications and two international patents. He is the former chair of the EAU Scientific Congress and is on the executive board of the Comprehensive Cancer Center of Southwestern Germany. His research and clinical interests include bladder and prostate cancer, as well as reconstructive surgery.

Non-Accredited

Washington, DC (UroToday.com) There is an increasing recognition that postoperative opioid prescriptions are contributing to the opioid crisis in the United States. This is in part due to the diversion of excess opioid medications, but also in part due to the new development of chronic opioid dependence among postoperative patients themselves, which is observed at a rate of 1-6% depending on how it is defined.

Non-Accredited

Washington, DC (UroToday.com) External beam radiotherapy is one of the standard treatment options for patients with localized prostate cancer requiring treatment. In many cases, concomitant androgen deprivation therapy (ADT) is prescribed on account of disease characteristics. In patients with locally advanced prostate cancer (EORTC 22863 and RTOG 86-10)1 and those with localized unfavourable risk disease,2 the addition of ADT has been shown to improve overall survival. However, ADT is well known to be associated with a number of side effects.  

Non-Accredited